Metagenomi Therapeutics (MGX) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Pelthos Therapeutics (PTHS) over the past year, losing 62.6% versus a loss of 74.9%. Pelthos Therapeutics is the larger company by market cap ($25.1 million vs $21.4 million), about 1.2 times the size. Pelthos Therapeutics converts more of its revenue into profit, with a net margin of -257.9% versus -348.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGX | PTHS |
|---|---|---|
| Share price | $0.565 | $6.38 |
| Market cap | $21.36M | $25.08M |
| 1-day change | -7.95% | -8.73% |
| YTD return | -65.12% | -79.42% |
| 1-year return | -62.58% | -74.88% |
| EPS (TTM) | $-2.50 | $-23.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $25.21M | $16.80M |
| Revenue growth (YoY) | -51.79% | — |
| Net income (latest FY) | $-87.87M | $-43.32M |
| Gross margin | — | 76.25% |
| Operating margin | -380.85% | -193.09% |
| Net margin | -348.54% | -257.93% |
| 52-week high | $1.87 | $31.62 |
| 52-week low | $0.562 | $6.02 |
| Distance from 52-week high | -69.79% | -79.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1138.94% | +732.92% |
| Average volume | 163.21K | 54.38K |
| Shares outstanding | 37.81M | 3.93M |
| Employees | 113 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed PTHS by 12.3 percentage points over the past year.
- Pelthos Therapeutics is more profitable, keeping -257.9 cents of every revenue dollar as net income versus -348.5 cents for Metagenomi Therapeutics.
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
MGX vs PTHS FAQ
Which is bigger, Metagenomi Therapeutics or Pelthos Therapeutics?
Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $25.08M compared with $21.36M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, MGX or PTHS?
MGX returned -62.58% over the past 12 months, compared with -74.88% for PTHS (price return, excluding dividends). Past performance does not predict future results.
Are Metagenomi Therapeutics and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.